Member Info for sajy

This tweet from Pur has probably helped. One of many records set recently at PureGold. More to come.

I do not expect the results of the trial and FDA submission to be merged. I expect Fum to announce the results of the trial by end of this month and state whether they have met the primary and secondary end points of the trial. The European trial was for 3 months and this trial is for 6 months as the FDA want to see if the efficacy diminishes over a longer period. Fum are confident that it doesn't.

Total Q1 & Q2 revenues of $32M, I think $20M of that will be profit. Therefore expecting approx $40M profit for the full year. The current Mcap is £30M and that basis I would say very undervalued.

As per Rns yesterday, funding partner announcement close.

I am in agreement with you Clive that we have some very high caliber people at Rene now, hence why I have a large holding. However I am annoyed at the options grated and will be letting Iain know when I speak to him. The option price should have been higher and they should have been performance related. I would have liked to see that the options could only be exercised after at least one Exosome licensing deal had been signed.

NED - Barbara bought 127K shares and CFO - Catherine bought 50K shares so far. As per Iain's comments at the recent presentation, I am expecting a lot more buying by Directors and staff.

I think the 50K, 32K and 31K buys today could also be director buys.

That’s just one director, Iain said several directors and staff would be buying. Expect a lot more buying, they clearly know how undervalued Rene is at present.
This is what I suggested would happen.

Agree Phil and my thoughts are the same. It's mainly about the Exosomes now and can they deliver, if the answer is yes then we are in for some big rises and that is the reason I have added substantially in the 30's. Current Mcap is about £16M and we have about £14M in cash, so everything the companies owns is valued at £2M. Each Exosome licensing deal is likely to involve £20-30M in upfront payment plus milestones and royalties. The upfront payment is worth about 50p on the SP and that's for one licensing deal. So you can imagine what will happen if we sign 2 or 3 licensing deals.

Look at all those buy's, I wonder if the directors have started buying or is it just PI's so far.

Excellent presentation and Iain came across very well. Just some of the points that caught my attention.

1. 7 Exosome collaborations ongoing and expect that to increase. Very excited with what they are seeing and will be providing update when they can.
2. Fosun investing a lot of money to progress CTX. Looking to license in other areas.
3. Already in discussions regarding sale of hRPC data.
4. Directors and staff will be buying shares.
5. No intentions to do a placing in such a dire market, expect to extend cash runway by signing deals and sale of legacy assets.
6. Very happy with the team assembled and will be recruiting CEO soon. Looking at both internal and external.

I mentioned on here a few weeks ago that directors would be buying and I know many of you questioned that. Today Iain confirmed that a few directors and staff would be buying and couldn't until now as they were on the inside.

Has the buying started? Quite a few buys starting to appear.

With cash at £14.5M at year end, that should extend the runway to end of calendar year2023, not mid year. With no trials ongoing and all collaborations expenses paid for by partners, the cash burn should be low compared to previous years. I think management are being over cautious by saying mid year 2023. Hopefully if we can sign at least one exosome licensing deal and sale of legacy asset then that will extend runway even further.

Not sure about others but I didn't expect any large amounts in this deal. For me the important thing is that this deal has been announced and when the results are announced on Monday, the closed period ends. This then allows the directors to buy shares. I am hoping they buy a decent amount of shares which should have a bigger impact than todays news.

Chat on the ADVFN board suggesting that ratification done, so hopefully an Rns tomorrow to confirm.

Use this email to get invite. fergus.young@camarco.co.uk

Hi Agadem, I can confirm that the company will provide an update on both the CC acquisition and debt restructure when they announce the full year results. I had posted the email reply I received from the company on here, but that post has been removed for some reason. Also the good news is that they said the CC acquisition was on track to complete in June.

I hold both Polx and Rene, but for you to say Polx is undervalued and Rene is a punt shows your an idiot who hasn't got a clue. So if the FDA rejected polx again what would it be worth then? Polx is a binary bet they have nothing else, so in my opinion it is polx that is a punt. Rene on the other hand are not a binary bet and if you had done your research you would know that.

Hi Surprised, I can assure you I don't ramp shares, instead carry out extensive research and post my thoughts. Like all humans I don't always get it right. Just to give you an example I am invested in POLX and after my research I posted that the company would be resubmitting to the FDA towards the end of Q1. I got a lot of abuse from posters on that board who accused me of lying. The company resubmitted on the 31st of March and all the abusers went all quiet and not one had the decency to apologise. Feel free to check my posts for POLX.

I have done the same for Rene and posted my thoughts from the research I have done. Again folks on here had a go at me when I said directors would be buying when closed period ends. One common mistake people make is that they are not appreciating the fact that we have a new team running Rene now and they need to judge these guys on their performance. All I will say is give them time and then judge them.

To show my faith I have bought heavily in the 30's and I now have a very large holding in Rene. I am absolutely convinced that the share price will be much higher once the news flow starts. In fact I expect it to do what my other large holding has done. I tipped Savannah Energy (SAVE) at 8p and it is now at 35p and I expect Rene to have a similar rise over time. I expect SAVE to rise considerably from 35p.